| Citation: |
BAI Yuming, LI Jin, SHI Lin, JIA Yongfeng, LIU Xia, YUN Fen. Transcriptomic Effects of LINC01614 on Lung Cancer A549 Cells and Relevance of Drug Resistance[J]. Cancer Research on Prevention and Treatment, 2023, 50(6): 573-580. DOI: 10.3971/j.issn.1000-8578.2023.22.0293
|
To investigate the biological role of LINC01614 in non-small cell lung cancer A549 cells and its drug resistance-related mechanism.
The CRISPR/Cas9 technology was used to construct the A549 cell model with knockdown of LINC01614. Transcriptome sequencing was performed on A549 cells knocked down with LINC01614. We validated the transcriptomic differential genes MCAM and ABCC3 at the gene level and MCAM at the protein level, detected the IC50 changes of A549 cells after knockdown of LINC01614 under the effect of different concentrations of cisplatin, and detected the effect of knockdown of LINC01614 on the migration ability of A549 cells.
Of the 2 713 DEGs after knockdown of LINC01614, a total of 1 626 genes were up-regulated and 1, 087 genes were down-regulated. GO analysis showed that DEGs were associated with intracellular signaling, cell adhesion, and so on. Meanwhile, the KEGG analysis showed that DEGs were associated with the Wnt signaling pathway, TGF-β signaling pathway, and Rap1 signaling pathway. Selection of drug resistance-associated gene ABCC3 from DEGs for validation with MCAM: qRT-PCR results showed that knockdown of LINC01614 significantly down-regulated the expression of MCAM (P<0.05) and upregulated the expression of ABCC3 on A549 cells (P<0.05). After knockdown of LINC01614, the protein expression of MCAM, was significantly decreased in A549 cells (P<0.05); the IC50 of A549 cells to cisplatin was significantly increased (P<0.05); and the scratch healing rate of A549 cells was also significantly decreased (P<0.05).
LINC01614 may be associated with the proliferation, invasion, and apoptotic pathways of A549 cells. In addition, LINC01614 may exert its migration ability through MCAM and chemoresistance to cisplatin through ABCC3.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. doi: 10.3322/caac.21708
|
| [2] |
Friedlaender A, Addeo A, Russo A, et al. Targeted Therapies in Early Stage NSCLC: Hype or Hope[J]. Int J Mol Sci, 2020, 21(17): 6329. doi: 10.3390/ijms21176329
|
| [3] |
Liu Z, Han L, Yu H, et al. LINC01619 promotes non-small cell lung cancer development via regulating PAX6 by suppressing microRNA-129-5p[J]. Am J Transl Res, 2020, 2(6): 2538-2553.
|
| [4] |
Xing C, Sun SG, Yue ZQ, et al. Role of lncRNA LUCAT1 in cancer[J]. Biomed Pharmacother, 2021, 134: 111158. doi: 10.1016/j.biopha.2020.111158
|
| [5] |
Gao Y, Shang S, Guo S, et al. Lnc2Cancer 3.0: an updated resource for experimentally supported lncRNA/circRNA cancer associations and web tools based on RNA-seq and scRNA-seq data[J]. Nucleic Acids Res, 2021, 49(D1): D1251-D1258. doi: 10.1093/nar/gkaa1006
|
| [6] |
Tripathi SC, Fahrmann JF, Celiktas M, et al. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway[J]. Cancer Res, 2017, 77(16): 4414-4425. doi: 10.1158/0008-5472.CAN-16-2874
|
| [7] |
Chandra F, Tania TF, Nurcahyanti ADR. Bixin and Fuxoxanthin Alone and in Combination with Cisplatin Regulate ABCC1 and ABCC2 Transcription in A549 Lung Cancer Cells[J]. J Pharm Bioallied Sci, 2023, 15(1): 15-20. doi: 10.4103/jpbs.jpbs_50_23
|
| [8] |
Zhang F, Wang J, Wang X, et al. CD146-mediated acquisition of stemness phenotype enhances tumour invasion and metastasis after EGFR-TKI resistance in lung cancer[J]. Clin Respir J, 2019, 13(1): 23-33. doi: 10.1111/crj.12976
|
| [9] |
Wang Q, Li K, Li X. Knockdown of LncRNA LINC00958 Inhibits the Proliferation and Migration of NSCLC Cells by MiR-204-3p/KIF2A Axis[J]. Cell Transplant, 2021, 30: 9636897211025500.
|
| [10] |
Liang H, Peng J. LncRNA HOTAIR promotes proliferation, invasion and migration in NSCLC cells via the CCL22 signaling pathway[J]. PLoS One, 2022, 17(2): e0263997. doi: 10.1371/journal.pone.0263997
|
| [11] |
Hua Q, Mi B, Xu F, et al. Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis[J]. Theranostics, 2020, 10(11): 4762-4778. doi: 10.7150/thno.43839
|
| [12] |
Geng Q, Li Z, Li X, et al. LncRNA NORAD, sponging miR-363-3p, promotes invasion and EMT by upregulating PEAK1 and activating the ERK signaling pathway in NSCLC cells[J]. J Bioenerg Biomembr, 2021, 53(3): 321-332. doi: 10.1007/s10863-021-09892-6
|
| [13] |
Zhao X, Jin X, Zhang Q, et al. Silencing of the lncRNA H19 enhances sensitivity to X-ray and carbon-ions through the miR-130a-3p/WNK3 signaling axis in NSCLC cells[J]. Cancer Cell Int, 2021, 21(1): 644. doi: 10.1186/s12935-021-02268-1
|
| [14] |
郑建洲, 白煜, 戚春建. LncRNA FENDRR通过调控ERK/MAPK影响肺鳞癌H226细胞增殖、迁移和凋亡[J]. 肿瘤防治研究, 2022, 49(6): 563-568. doi: 10.3971/j.issn.1000-8578.2022.21.1193
Zheng JZ, Bai Y, Qi CJ. LncRNA FENDRR Affect Proliferation, Migration and Apoptosis of Lung Squamous Cell Carcinoma H226 Cells via ERK/MAPK Signaling Pathway[J]. Zhong Liu Fang Zhi Yan Jiu, 2022, 49(6): 563-568. doi: 10.3971/j.issn.1000-8578.2022.21.1193
|
| [15] |
Zhen Q, Gao LN, Wang RF, et al. LncRNA DANCR Promotes Lung Cancer by Sequestering miR-216a[J]. Cancer Control, 2018, 25(1): 1073274818769849.
|
| [16] |
Deng H, Qianqian G, Ting J, et al. miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1[J]. Biomed Pharmacother, 2018, 106: 1072-1081. doi: 10.1016/j.biopha.2018.07.024
|
| [17] |
Liu AN, Qu HJ, Yu CY, et al. Knockdown of LINC01614 inhibits lung adenocarcinoma cell progression by up-regulating miR-217 and down-regulating FOXP1[J]. J Cell Mol Med, 2018, 22(9): 4034-4044. doi: 10.1111/jcmm.13483
|
| [18] |
de Waart DR, van de Wetering K, Kunne C, et al. Oral availability of cefadroxil depends on ABCC3 and ABCC4[J]. Drug Metab Dispos, 2012, 40(3): 515-521. doi: 10.1124/dmd.111.041731
|
| [19] |
Ramírez-Cosmes A, Reyes-Jiménez E, Zertuche-Martínez C, et al. The implications of ABCC3 in cancer drug resistance: can we use it as a therapeutic target?[J]. Am J Cancer Res, 2021, 11(9): 4127-4140.
|
| [20] |
Chen J, Dang Y, Feng W, et al. SOX18 promotes gastric cancer metastasis through transactivating MCAM and CCL7[J]. Oncogene, 2020, 39(33): 5536-5552. doi: 10.1038/s41388-020-1378-1
|
Figures(8) / Tables(1)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: